PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2017.43820185041252-1259Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)Yoon Ji Choi, Hye Sook Kim, Se Hoon Park, Bong-Seog Kim, Kyoung Ha Kim, Hyo Jin Lee, Hong Suk Song, Dong-Yeop Shin, Ha Young Lee, Hoon-Gu Kim, Kyung Hee Lee, Jae Lyun Lee, Kyong Hwa Parkhttp://e-crt.org/upload/pdf/crt-2017-438.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.438, http://www.e-crt.org/upload/pdf/crt-2017-438.pdf
Annals of Oncology10.1093/annonc/mdw372.16201627vi249A phase II study of TKI258 in patients with castration-resistant prostate cancer (KCSG-GU11-05)Y.J. Choi, H.S. Kim, S.H. Park, B.S. Kim, K.H. Kim, H.J. Lee, H.S. Song, D.Y. Shin, H.Y. Lee, H.-G. Kim, K.H. Lee, J.-L. Lee, K.H. Parkhttps://api.elsevier.com/content/article/PII:S0923753419443615?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419443615?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/27/suppl_6/732P/19450473/mdw372.16.pdf
Clinical Genitourinary Cancer10.1016/j.clgc.2019.07.0102019175e886-e887Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot StudyDavid O’Reillyhttps://api.elsevier.com/content/article/PII:S1558767319302265?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1558767319302265?httpAccept=text/plain
Cancers10.3390/cancers30334492011333449-3460Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate CancerRobert J. Amato, L. Michael Glode, Jeremy Podolnick, Robert Knight, David Crawfordhttp://www.mdpi.com/2072-6694/3/3/3449/pdf
British Journal of Cancer10.1038/bjc.2012.33920121075808-813Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials ConsortiumT M Beer, D C Smith, A Hussain, M Alonso, J Wang, M Giurescu, K Roth, Y Wanghttp://www.nature.com/articles/bjc2012339.pdf, http://www.nature.com/articles/bjc2012339, http://www.nature.com/articles/bjc2012339.pdf
The Prostate10.1002/pros.214852011728834-845Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapyMasanori Noguchi, Fukuko Moriya, Shigetaka Suekane, Kei Matsuoka, Gaku Arai, Satoko Matsueda, Tetsuro Sasada, Akira Yamada, Kyogo Itohhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.21485, https://onlinelibrary.wiley.com/doi/full/10.1002/pros.21485
Clinical Genitourinary Cancer10.1016/j.clgc.2013.09.001201412127-32Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II StudyChadi Nabhan, Anand Patel, Dana Villines, Kathy Tolzien, Susan K. Kelby, Timothy M. Lestingihttps://api.elsevier.com/content/article/PII:S1558767313002127?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1558767313002127?httpAccept=text/plain
Clinical Genitourinary Cancer10.1016/j.clgc.2021.07.0132021A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone MetastasesNobuaki Matsubara, Hirotsugu Uemura, Satoshi Nagamori, Hiroyoshi Suzuki, Hiroji Uemura, Go Kimurahttps://api.elsevier.com/content/article/PII:S155876732100152X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S155876732100152X?httpAccept=text/plain
BMC Cancer10.1186/1471-2407-13-6132013131A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling timeMasanori Noguchi, Fukuko Moriya, Shigetaka Suekane, Rei Ohnishi, Satoko Matsueda, Tetsuro Sasada, Akira Yamada, Kyogo Itohhttp://link.springer.com/content/pdf/10.1186/1471-2407-13-613.pdf, http://link.springer.com/article/10.1186/1471-2407-13-613/fulltext.html, http://link.springer.com/content/pdf/10.1186/1471-2407-13-613
The Prostate10.1002/pros.20813200868131461-1466Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancerManpreet K. Chadha, Umeer Ashraf, David Lawrence, Lili Tian, Ellis Levine, Carrie Silliman, Paul Escott, Valencia Payne, Donald L. Trumphttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.20813, https://onlinelibrary.wiley.com/doi/full/10.1002/pros.20813